Annual General Meeting

Machavert’s Annual General Meeting took place on June 27 in Prague, Czech Republic. The Machavert management team presented a progress update and discussed future directions with its current shareholders in the company’s Strategic Plan. The presented near term goals included obtaining a 3rd party confirmation of anti-cancer efficacy, as well as safety of our leading drug candidate MP1000.

In addition, Stanislav Pavlin, Independent Executive Advisor and former Principal Assets Manager, Vodafone Group, and was named Chairman of the Board, joining Board Members Michal Drozd, Radek Stavinoha and Jakub Staszak-Jirkovsky.

“I am excited to be a part of such an innovative company that’s building the way of the future in bio-pharmaceuticals.” said Stanislav. “I look forward to helping guide Machavert on that path and impacting the quality of life for the many patients suffering from life threatening diseases.”

Also introduced at the Annual General Meeting were new additions to the Science Advisory Board and a new Business Advisor: Detlef Schultz, former CEO of Vodafone Procurement Company and Global Supply Chain Management Director at Vodafone.